This Tuesday the institutional working group of the plan on T-CAR therapies in the SNS meets. At the entrance of the meeting, the Minister of Health, María Luisa Carcedo, has made an estimate of the number of reference hospitals with which, from the outset, Spain could count on to offer T-CAR therapies: “There will be between 5 and 7” , Carcedo has calculated. It should be remembered that, as DM advanced, the plan foresees that the number of CSUR varies according to the assistance needs.
The minister has also revealed that, as part of the development of the strategic plan on these therapies, the first criteria for their use have already been defined: there are nine for acute lymphoblastic leukemia in children and ten for B lymphoma in adults.
As diariomedico.com reported, one of the objectives of the plan is to prioritize the public -cademic- development of T-CAR therapies, so that there are alternatives to commercial developments -there are already two approved, one from Novartis and another from Gilead-. For this reason, Carcedo has cited the development of a T-CAR at the Hospital Clínic de Barcelona, ??in collaboration with the Carlos III Health Institute, which is already in phase II.
The minister added that the short-term objective “is to expand the number of patients covered with academic T-CAR, for example, in patients older than 25 years with acute lymphoblastic leukemia.” Carcedo concluded by insisting that the plan seeks an introduction of the T-CARs in the SNS “planned, equitable, safe and efficient”.
In Distefar we echo this news whose objective is to expand the number of patients covered with academic T-CAR.